Sapisochín Gonzalo, Fernández de Sevilla Elena, Echeverri Juan, Charco Ramón
Gonzalo Sapisochín, Elena Fernández de Sevilla, Juan Echeverri, Ramón Charco, Department of HBP Surgery and Transplantation, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, 08037 Barcelona, Spain.
World J Hepatol. 2015 Oct 8;7(22):2396-403. doi: 10.4254/wjh.v7.i22.2396.
Cholangiocarcinoma is a malignant tumor of the biliary system that can be classified into intrahepatic (iCCA), perihiliar (phCCA) and distal. Initial experiences with orthotopic liver transplantation (OLT) for patients with iCCA and phCCA had very poor results and this treatment strategy was abandoned. In the last decade, thanks to a strict selection process and a neoadjuvant chemoradiation protocol, the results of OLT for patients with non-resectable phCCA have been shown to be excellent and this strategy has been extended worldwide in selected transplant centers. Intrahepatic cholangiocarcinoma is a growing disease in most countries and can be diagnosed both in cirrhotic and in non-cirrhotic livers. Even though OLT is contraindicated in most centers, recent investigations analyzing patients that were transplanted with a misdiagnosis of HCC and were found to have an iCCA have shown encouraging results. There is some information suggesting that patients with early stages of the disease could benefit from OLT. In this review we analyze the current state-of-the-art of OLT for cholangiocarcinoma as well as the new insights and future perspectives.
胆管癌是一种胆道系统的恶性肿瘤,可分为肝内胆管癌(iCCA)、肝门周围胆管癌(phCCA)和远端胆管癌。最初对iCCA和phCCA患者进行原位肝移植(OLT)的经验结果非常糟糕,这种治疗策略被放弃了。在过去十年中,由于严格的筛选过程和新辅助放化疗方案,OLT治疗不可切除phCCA患者的结果已被证明非常出色,并且这种策略已在选定的移植中心推广至全球。在大多数国家,肝内胆管癌的发病率正在上升,在肝硬化和非肝硬化肝脏中均可诊断。尽管大多数中心都将OLT列为禁忌,但最近对那些被误诊为肝癌而接受移植且最终被发现患有iCCA的患者进行分析的研究显示出了令人鼓舞的结果。有一些信息表明,疾病早期的患者可能从OLT中获益。在这篇综述中,我们分析了胆管癌OLT的当前技术水平以及新见解和未来展望。